Home > Insider Trading > Filing (0001179110-16-025240)

Filing Details

Accession Number:: 0001179110-16-025240
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-05-20 16:41:16
Reporting Period:: 2016-05-18

Filing Date:: 2016-05-20
Accepted Time:: 2016-05-20 16:41:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1280600	Acceleron Pharma Inc	XLRN	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1586745	L John Knopf	128 Sidney Street Cambridge MA 02139	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-05-18	24,090	$5.08	160,674	No	4	M	Direct
Common Stock	Disposition	2016-05-18	36,590	$33.04	124,084	No	4	S	Direct
Common Stock	Acquisiton	2016-05-19	37,623	$5.08	161,707	No	4	M	Direct
Common Stock	Disposition	2016-05-19	37,623	$33.04	124,084	No	4	S	Direct
Common Stock	Acquisiton	2016-05-20	25,787	$5.08	149,871	No	4	M	Direct
Common Stock	Disposition	2016-05-20	25,787	$33.17	124,084	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2016-05-18	24,090	$0.00	24,090	$5.08
Common Stock	Option to Purchase Common Stock	Disposition	2016-05-19	37,623	$0.00	37,623	$5.08
Common Stock	Option to Purchase Common Stock	Disposition	2016-05-20	25,787	$0.00	25,787	$5.08

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
178,043	2018-03-27	No	4	M	Direct
140,420	2018-03-27	No	4	M	Direct
114,633	2018-03-27	No	4	M	Direct

Footnotes

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.30, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.21, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.64, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.